GLAXO share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on GLAXO. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for GLAXO is 82 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for GLAXO is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

GLAXO sits in Healthcare (mid cap), indicative market cap ~42,469 cr (indicative), ISIN INE159A01016. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on GlaxoSmithKline Pharmaceuticals Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on GLAXO is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, GlaxoSmithKline Pharmaceuticals Limited sits in the Scanned tier with a setup score of 73/100 (technical 86, fundamental 83). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 11 GLAXO earnings calls going back to 2022-08-31, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

GlaxoSmithKline Pharmaceuticals Limited reported a net profit of Rs 278 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +5.7% year on year. The figure is from the company's official NSE filing.

GlaxoSmithKline Pharmaceuticals Limited reported revenue of Rs 995 cr for Q4 FY26. That is +2.1% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives GlaxoSmithKline Pharmaceuticals Limited's Q4 FY26 result a Result Pulse of 58 out of 100, with a verdict of Steady. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

GlaxoSmithKline Pharmaceuticals Ltd's two most material recent disclosures are a regulatory dated 08 Jul 2026, "Certificate under SEBI (Depositories and Participants)…", and an agm / egm dated 30 Jun 2026, "Proceedings of Annual General Meeting held on Jun 30,…". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. GlaxoSmithKline Pharmaceuticals Ltd filed a dividend disclosure on 29 May 2026, filed as "Dividend - Rs 57 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

GlaxoSmithKline Pharmaceuticals Ltd's most recent board-meeting disclosure on record dated 05 Jun 2026 reads "Notice of Annual General Meeting to be held on Jun 30, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.